Business Context and Reporting Period
This Form 6-K/A filing by GlaxoSmithKline plc covers the period ending February 2013. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility under the company's ShareReward Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share acquisition transactions.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details routine share acquisitions by senior management on February 11, 2013, at a price of 1450.62 pence per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share interests.
Important Facts for Investors
- Senior management, including Sir Andrew Witty, acquired shares via the ShareReward Plan on February 11, 2013.
- The transaction price was 1450.62 pence per Ordinary Share.
- Acquisitions consisted of personal contributions matched by company contributions (e.g., 9 shares personal + 9 shares company for most directors).
- This filing does not contain financial performance data for the period.